Amerikan Kanser Ara\u015ft\u0131rmalar\u0131 Derne\u011fi (AACR) 2025 toplant\u0131s\u0131nda, The University of Texas MD Anderson Kanser Merkezi\u2019nden ara\u015ft\u0131rmac\u0131lar, kanser tedavisinde yeni d\u00f6nemi i\u015faret eden \u00f6nemli geli\u015fmeleri a\u00e7\u0131klad\u0131. Bu \u00e7al\u0131\u015fmalar aras\u0131nda, ki\u015fiye \u00f6zel kanser a\u015f\u0131lar\u0131, metastaz odakl\u0131 radyoterapi ve gen susturma amac\u0131yla tasarlanm\u0131\u015f m\u00fchendislik \u00fcr\u00fcn\u00fc ekzomalar kullan\u0131m\u0131 yer ald\u0131. Ayr\u0131ca, geli\u015fmi\u015f kat\u0131 t\u00fcm\u00f6rlerde hedefe y\u00f6nelik bir ATR kinaz inhibit\u00f6r\u00fc de sunuldu. Ara\u015ft\u0131rmalar, t\u00fcm\u00f6r biyolojisi, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi mod\u00fclasyonu ve tedavi hedeflemesinde yenilik\u00e7i y\u00f6ntemler geli\u015ftirerek onkoloji alan\u0131n\u0131n gelece\u011fine \u0131\u015f\u0131k tutuyor.<\/p>\n
\u0130lk \u00e7al\u0131\u015fma, ba\u011f\u0131\u015f\u0131kl\u0131k tedavilerine genellikle diren\u00e7li olan mikrosatellit stabil (MSS) metastatik kolorektal kanser (mKRK) alt t\u00fcr\u00fcne odakland\u0131. Dr. Saurav Daniel Haldar ve Dr. Michael Overman liderli\u011findeki faz I klinik ara\u015ft\u0131rma, NeoAg-VAX ad\u0131 verilen ki\u015fiselle\u015ftirilmi\u015f bir a\u015f\u0131 platformunu test etti. Bu a\u015famada, hastalar\u0131n t\u00fcm\u00f6rlerinden elde edilen genetik de\u011fi\u015fikliklere dayal\u0131 olarak tasarlanan 10 adede kadar t\u00fcm\u00f6r \u00f6zg\u00fc proteini i\u00e7eren a\u015f\u0131, hem tek ba\u015f\u0131na hem de PD-1 inhibit\u00f6r\u00fc olan pembrolizumab ile birlikte uyguland\u0131. NeoAg-VAX, hastalar\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k sistemini etkili bi\u00e7imde kanser h\u00fccrelerini tan\u0131y\u0131p yok etmeye y\u00f6nlendirerek yeni bir tedavi perspektifi sundu.<\/p>\n
NeoAg-VAX a\u015famas\u0131nda ciddi yan etki g\u00f6zlenmedi ve uygulanan hastalar\u0131n \u00e7o\u011funda imm\u00fcn yan\u0131tlar ba\u015far\u0131l\u0131 bi\u00e7imde tetiklendi. T\u00fcm\u00f6r mikro ortam\u0131nda incelenen ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccre yap\u0131s\u0131nda ya\u015fanan dinamik de\u011fi\u015fiklikler, MSS kolorektal t\u00fcm\u00f6rlerde ba\u011f\u0131\u015f\u0131kl\u0131k ka\u00e7\u0131\u015f\u0131n\u0131 a\u015fmak i\u00e7in yeni stratejiler geli\u015ftirilmesine zemin haz\u0131rlad\u0131. Ara\u015ft\u0131rmac\u0131lar bu bulgular\u0131n, a\u015f\u0131 tasar\u0131mlar\u0131n\u0131n optimize edilmesi ve sistemik tedavi y\u00f6ntemleri ile kombinasyonlar\u0131n\u0131n geli\u015ftirilmesi ad\u0131na \u00f6nemli oldu\u011funu belirtiyor. Bu \u00e7al\u0131\u015fma, t\u00fcm\u00f6re y\u00f6nelik ki\u015fiselle\u015ftirilmi\u015f imm\u00fcnoterapilerin, so\u011fuk mikro ortam sorununu a\u015fmak i\u00e7in kritik bir ad\u0131m oldu\u011funu ortaya koydu.<\/p>\n
Bir di\u011fer klinik ara\u015ft\u0131rmada ise, metastatik klar h\u00fccreli b\u00f6brek kanseri (ccRCC) tedavisinde sistemik tedavilerin yan etkileri azalt\u0131ld\u0131. Dr. Chad Tang ve Dr. Pavlos Msaouel\u2019in liderlik etti\u011fi faz II \u00e7al\u0131\u015fmada, sistemik ila\u00e7 tedavisine ihtiya\u00e7 olmadan sadece metastatik lezyonlara odaklanan radyoterapi y\u00f6ntemi denendi. Toplam 121 oligometastatik ccRCC hastas\u0131, metastaz odakl\u0131 radyoterapi ald\u0131. Bu yakla\u015f\u0131m, hastalar\u0131n genel sistemik ba\u011f\u0131\u015f\u0131kl\u0131k bask\u0131lanmas\u0131 ya\u015famadan, tedaviye ba\u011fl\u0131 y\u00fcksek dereceli yan etkilerinden korundu.<\/p>\n
Metastaz odakl\u0131 radyoterapi alan hastalarda medyan progresyonsuz ya\u015fam s\u00fcresi 18 ay olarak kaydedildi. Sistemik tedaviye ba\u015flama olmadan ge\u00e7en s\u00fcre ise 34 ay olarak belirlendi. \u0130ki ve \u00fc\u00e7 y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131 s\u0131ras\u0131yla %94 ve %87 olarak kayda de\u011fer d\u00fczeylerde ger\u00e7ekle\u015fti. Sistemik behandling olmadan dahi metastazlar\u0131n lokal olarak kontrol alt\u0131na al\u0131nabildi\u011finin ve hastalar\u0131n ya\u015fam kalitesinin korunabildi\u011finin kan\u0131t\u0131 olan bu sonu\u00e7lar, metastatik b\u00f6brek kanserinde tedavi paradigmas\u0131n\u0131 de\u011fi\u015ftirebilir.<\/p>\n
Hastalara \u00f6zg\u00fc tedavi kararlar\u0131n\u0131n desteklenmesi i\u00e7in, ara\u015ft\u0131rmac\u0131lar t\u00fcm\u00f6re \u00f6zel alt dola\u015f\u0131mdaki t\u00fcm\u00f6r DNA\u2019s\u0131n\u0131 (ctDNA) tespit eden yeni bir test kulland\u0131. Molek\u00fcler kal\u0131nt\u0131 hastal\u0131k (MRD) saptayan bu s\u0131v\u0131 biyopsi y\u00f6ntemi, kimin metastaz odakl\u0131 radyoterapi ile daha uzun s\u00fcre sistemik tedavisiz kalaca\u011f\u0131n\u0131 belirleyerek, hastalar\u0131n a\u015f\u0131r\u0131 sistemik tedaviye maruz kalmas\u0131n\u0131 \u00f6nl\u00fcyor. MRD negatif olan hastalar, sistemik tedavi ba\u015flanana dek g\u00f6zlenen ya\u015fam s\u00fcrelerinde istatistiksel olarak anlaml\u0131 uzama g\u00f6sterdi. Bu geli\u015fme, s\u0131v\u0131 biyopsi teknolojilerinin onkolojide bireyselle\u015ftirilmi\u015f tedavi kararlar\u0131n\u0131n temel arac\u0131 olaca\u011f\u0131n\u0131n \u00f6nemini vurguluyor.<\/p>\n
\u00dc\u00e7\u00fcnc\u00fc yenilik\u00e7i y\u00f6ntemde ise, pankreas kanserinde s\u0131k g\u00f6r\u00fclen KRAS G12D mutasyonu hedef al\u0131nd\u0131. Dr. Valerie LeBleu ve ekibinin \u00f6nc\u00fcl\u00fc\u011f\u00fcnde ger\u00e7ekle\u015ftirilen ilk-in-insan faz I \u00e7al\u0131\u015fmada, kemik ili\u011fi kaynakl\u0131 h\u00fccrelerden elde edilen ve k\u00fc\u00e7\u00fck m\u00fcdahaleler yapan RNA (siRNA) ta\u015f\u0131yan m\u00fchendislik \u00fcr\u00fcn\u00fc ekzomlar denendi. Bu ekzomlar, mutant KRAS G12D genini susturarak pankreas kanserinde t\u00fcm\u00f6r ilerlemesini molek\u00fcler d\u00fczeyde engellemeyi ama\u00e7lad\u0131.<\/p>\n
On iki hastan\u0131n kat\u0131ld\u0131\u011f\u0131 \u00e7al\u0131\u015fmada verilen ekzom tedavisinin g\u00fcvenli oldu\u011fu, doz s\u0131n\u0131rlay\u0131c\u0131 toksisite g\u00f6r\u00fclmedi\u011fi rapor edildi. Tedavi g\u00f6ren hastalardan alt\u0131s\u0131nda hedef lezyonlarda hastal\u0131k stabilitesi g\u00f6zlendi. Ayr\u0131ca dola\u015f\u0131mdaki KRAS G12D DNA seviyelerinde azalma, gen susturma etkisinin klinik yans\u0131mas\u0131 oldu. \u00d6n klinik veriler, bu ekzomlar\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k engelleyici t\u00fcm\u00f6r mikro ortam\u0131n\u0131 yeniden programlayarak ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131 blokajlar\u0131yla sinerji olu\u015fturdu\u011funu g\u00f6sterdi. Bu da, kombinasyon tedavilerinin denenece\u011fi faz II \u00e7al\u0131\u015fmalar i\u00e7in umut verici temeller sunuyor.<\/p>\n
Bu klinik ara\u015ft\u0131rmalar\u0131n tamamlay\u0131c\u0131s\u0131 olarak, MD Anderson\u2019un Terap\u00f6tik Ke\u015fif b\u00f6l\u00fcm\u00fcnde geli\u015ftirilen ART0380 adl\u0131 ATR kinaz inhibit\u00f6r\u00fcn\u00fcn erken klinik verileri de AACR 2025\u2019de sunuldu. ART0380, DNA hasar yan\u0131t\u0131ndaki kusurlar\u0131 hedef alarak, ileri evre kat\u0131 t\u00fcm\u00f6rlerde kullan\u0131l\u0131yor. Preklinik modellerde y\u00fcksek potansiyelli antit\u00fcm\u00f6r aktivitesi g\u00f6steren bu ila\u00e7, molek\u00fcler t\u00fcm\u00f6r \u00f6zelliklerine g\u00f6re hasta se\u00e7imini optimize etme yakla\u015f\u0131m\u0131yla birlikte kullan\u0131larak tedavi etkinli\u011fi art\u0131r\u0131lmaya \u00e7al\u0131\u015f\u0131l\u0131yor. Bu yenilikler, hassas onkolojide daha etkin ve hasta dostu terapilerin geli\u015ftirilmesine kap\u0131 aral\u0131yor.<\/p>\n
Bu \u00e7al\u0131\u015fmalar, molek\u00fcler hassasiyetler \u00fczerine kurulan ve ba\u011f\u0131\u015f\u0131kl\u0131k ortam\u0131n\u0131 detayl\u0131 bi\u00e7imde d\u00fczenleyen yeni nesil tedavilerin kanser y\u00f6netiminde \u00e7\u0131\u011f\u0131r a\u00e7aca\u011f\u0131n\u0131 ortaya koyuyor. Biyoinformatik analizlerin, molek\u00fcler tan\u0131 testlerinin ve ekzom benzeri yenilik\u00e7i ta\u015f\u0131y\u0131c\u0131 sistemlerin entegre edilmesiyle, MD Anderson ara\u015ft\u0131rmac\u0131lar\u0131, daha etkili ve ki\u015fiye \u00f6zel onkolojik bak\u0131m\u0131n \u00f6n\u00fcn\u00fc a\u00e7\u0131yor. Kanser biyolojisi, tedavi diren\u00e7 mekanizmalar\u0131 ve klinik uygulamalara y\u00f6nelik kavray\u0131\u015flar, ger\u00e7ek d\u00fcnyadaki hasta y\u00f6netimine do\u011frudan yans\u0131t\u0131labiliyor.<\/p>\n
H\u00fccre ve gen hedefli tedaviler, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ile uyumlu \u015fekilde kombine edilerek hem yan etkiler azalt\u0131l\u0131yor hem de tedavi etkinli\u011fi art\u0131r\u0131l\u0131yor. Ki\u015fiselle\u015ftirilmi\u015f a\u015f\u0131lar, s\u0131v\u0131 biyopsiyle y\u00f6nlendirilen radyoterapi ve gen susturma ekzom teknolojisi, kanser tedavisinde hasta merkezli ve hassas yakla\u015f\u0131mlar\u0131n sembollerini ta\u015f\u0131yor. Bu geli\u015fmeler, \u00f6zellikle refrakter ve nadir molek\u00fcler alt gruplar\u0131 olan hastalar i\u00e7in umut veriyor.<\/p>\n
Dr. Haldar, imm\u00fcn sistemin \u00f6zg\u00fcn yan\u0131t kapasitesinin t\u00fcm\u00f6r mikro ortam\u0131na g\u00f6re uyarlanmas\u0131n\u0131n, m\u00fccadelede belirleyici oldu\u011funu vurgulad\u0131. Dr. Tang ise, ctDNA\u2019n\u0131n b\u00f6brek kanserindeki tedavi kararlar\u0131n\u0131 ki\u015fiselle\u015ftiren \u00f6nemli bir ara\u00e7 oldu\u011funu belirtti. Dr. LeBleu\u2019nin ekibi ise ekzom arac\u0131l\u0131\u011f\u0131yla hedef mRNA\u2019lar\u0131n susturulmas\u0131 yakla\u015f\u0131m\u0131yla, kat\u0131 t\u00fcm\u00f6rlerde ila\u00e7 hedefleme paradigmas\u0131n\u0131 de\u011fi\u015ftirebilecek bir ad\u0131m att\u0131.<\/p>\n
Yakla\u015fan faz II \u00e7al\u0131\u015fmalar\u0131 ve geni\u015fletilmi\u015f translasyonel ara\u015ft\u0131rmalar, bu yenilik\u00e7i tedavi modalitelerinin etkinlik ve g\u00fcvenli\u011fini teyit etmek ve standart bak\u0131m rejimleri olarak yerle\u015ftirmek i\u00e7in kritik olacak. Kolorektal, b\u00f6brek ve pankreas kanserlerinin yan\u0131 s\u0131ra di\u011fer solid t\u00fcm\u00f6rler i\u00e7in bu geli\u015fmeler, modern onkolojinin gelecekteki y\u00f6n\u00fcn\u00fc g\u00f6stermekle kalmay\u0131p, kanser tedavisini daha etkili, ki\u015fiye \u00f6zel ve sistemik toksisiteyi minimumda tutan hale getirecek.<\/p>\n
MD Anderson\u2019\u0131n AACR 2025\u2019te sundu\u011fu bu \u00f6nc\u00fc \u00e7al\u0131\u015fmalar, kanserle m\u00fccadelede bilimsel titizlikle klinik yenili\u011fin m\u00fckemmel bir birle\u015fimi oldu\u011funu ortaya koyuyor. Kanserle m\u00fccadelede hassas t\u0131p, ger\u00e7ek zamanl\u0131 molek\u00fcler izleme ve yenilik\u00e7i tedavi stratejilerinin entegrasyonu, hastalar\u0131n ya\u015fam kalitesini ve tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131rma konusunda \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olarak \u00f6ne \u00e7\u0131k\u0131yor. Detayl\u0131 etkinlik bilgilerine ise MD Anderson\u2019\u0131n AACR 2025 web platformu \u00fczerinden ula\u015f\u0131labilecek.<\/p>\n
**Ara\u015ft\u0131rma Konusu**: Personalized cancer vaccines, metastasis-directed radiation therapy, engineered exosome-mediated gene silencing, targeted ATR kinase inhibition in advanced solid tumors
\n**Makale Ba\u015fl\u0131\u011f\u0131**: Emerging Advances in Targeted Cancer Therapies Unveiled at AACR 2025 by MD Anderson Researchers
\n**Haberin Yay\u0131n Tarihi**: April 25, 2025
\n**Web References**:
\n– AACR Annual Meeting 2025
\n– MD Anderson AACR 2025
\n– Abstract CT012
\n– Abstract CT132
\n– Abstract CT265
\n– Clinical Cancer Research Article on ART0380
\n**Anahtar Kelimeler**: Kanser ara\u015ft\u0131rmalar\u0131, Kombinasyon terapileri, Molek\u00fcler hedefler, Hedef mRNA, H\u00fccre tedavileri, Metastaz, Kolorektal kanser, Ekzomlar, Pankreas kanseri, B\u00f6brek kanseri, Pankreas t\u00fcm\u00f6rleri<\/p>\n","protected":false},"excerpt":{"rendered":"
Amerikan Kanser Ara\u015ft\u0131rmalar\u0131 Derne\u011fi (AACR) 2025 toplant\u0131s\u0131nda, The University of Texas MD Anderson Kanser Merkezi\u2019nden ara\u015ft\u0131rmac\u0131lar, kanser tedavisinde yeni d\u00f6nemi i\u015faret eden \u00f6nemli geli\u015fmeleri a\u00e7\u0131klad\u0131. Bu \u00e7al\u0131\u015fmalar aras\u0131nda, ki\u015fiye \u00f6zel kanser a\u015f\u0131lar\u0131, metastaz odakl\u0131 radyoterapi ve gen susturma amac\u0131yla tasarlanm\u0131\u015f m\u00fchendislik \u00fcr\u00fcn\u00fc ekzomalar kullan\u0131m\u0131 yer ald\u0131. Ayr\u0131ca, geli\u015fmi\u015f kat\u0131 t\u00fcm\u00f6rlerde hedefe y\u00f6nelik bir ATR kinaz…<\/p>\n","protected":false},"author":1,"featured_media":3920,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3329,3330,3327,3326,3328],"tmauthors":[],"class_list":{"0":"post-3919","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-atr-kinaz-inhibitoru-kati-tumor-tedavisi","9":"tag-kanser-immunoterapisi-yenilikleri","10":"tag-kisisellestirilmis-kanser-asilari-mkrk-tedavisi","11":"tag-md-anderson-kanser-klinik-denemeleri","12":"tag-metastaz-odakli-radyoterapi-bobrek-kanseri"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/MD-Anderson-Klinik-Denemelerinden-Umit-Veren-Sonuclar-1745603081.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3919"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3919\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3920"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3919"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}